Lisata (LSTA) 8-K: Q3 2025 results press release and exhibits

Rhea-AI Filing Summary

Lisata Therapeutics (LSTA) furnished an 8-K announcing a press release with financial results for the third quarter ended September 30, 2025, and a corporate presentation. The materials are included as Exhibits 99.1 and 99.2.

These disclosures were provided under Regulation FD and are being furnished, not filed, and therefore are not subject to Section 18 of the Exchange Act nor incorporated by reference except as expressly stated.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0000320017false00003200172025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

November 6, 2025

Date of Report (date of earliest event reported)

LISATA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-33650

22-2343568

(State or other jurisdiction of incorporation or organization)

(Commission File Number)

(I.R.S. Employer Identification No.)

110 Allen Road, Second Floor, Basking Ridge, NJ 07920

(Address of Principal Executive Offices)(ZipCode)

(908) 842-0100

Registrant's telephone number, including area code

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.001 per share			LSTA			The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

☐ Emerging growth company

o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

The information in Item 7.01 is incorporated by reference.

Item 7.01 Regulation FD Disclosure.

On November 6, 2025, Lisata Therapeutics, Inc. (the "Company") issued a press release in connection with its financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference.

A copy of a slide presentation that the Company will use at investor and industry conferences and presentations is attached to this Current Report as Exhibit 99.2 and is incorporated herein solely for purposes of this Item 7.01 disclosure. 

The information in this Item 7.01, including Exhibits 99.1 and 99.2 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01, including Exhibits 99.1 and 99.2 attached hereto, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, except as otherwise expressly stated in such filing.

Item 9.01. Financial Statement and Exhibits.

Exhibit No.			Description
99.1			Press Release, dated November 6, 2025
99.2			Lisata Therapeutics, Inc. Corporate Presentation, November 6, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LISATA THERAPEUTICS, INC.

By: /s/ David J. Mazzo            

Name: David J. Mazzo, PhD

Title: President & Chief Executive Officer

Dated: November 6, 2025

FAQ

What did Lisata Therapeutics (LSTA) disclose in this 8-K?

The company furnished a press release with financial results for the third quarter ended September 30, 2025, and a corporate presentation.

Which exhibits are attached to Lisata Therapeutics' 8-K?

Exhibit 99.1 is the November 6, 2025 press release; Exhibit 99.2 is the corporate presentation dated November 6, 2025.

Are the Q3 2025 materials considered filed with the SEC?

No. They were furnished under Regulation FD and are not deemed filed or subject to Section 18 of the Exchange Act.

What period do the financial results cover for Lisata Therapeutics (LSTA)?

The third quarter ended September 30, 2025.

Where is Lisata Therapeutics' common stock listed and under what symbol?

On The Nasdaq Capital Market under the symbol LSTA.

Which 8-K items does Lisata reference for this disclosure?

Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).